Tempus AI wins FDA clearance for ECG-MR tool to flag undiagnosed mitral regurgitation

By Public Technologies
  • Tempus AI received FDA 510(k) clearance for ECG-MR, an AI tool that flags signs linked to undiagnosed moderate or severe mitral regurgitation.
  • The software analyzes standard resting 12-lead ECGs to identify high-risk patients for follow-up evaluation such as diagnostic imaging.
  • The clearance expands its ECG-AI portfolio to four FDA-cleared products spanning arrhythmia, heart function, pulmonary vascular, and valvular disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609280800BIZWIRE_USPR_____20260928_BW106625) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.